Chidamide: Chidamide tablets,：Oral administration at a dose of 20 mg (4 tablets) per intake, twice weekly, with an interval of no less than 3 days between the two doses .
Azacitidine (AZA): Subcutaneous injection at a dose of 100 mg/day on Days 1-7
Prednisone: Oral administration at a dose of 20 mg/day, taken after breakfast.
Cyclophosphamide: Oral administration at a dose of 50 mg/day, taken after lunch.
Thalidomide (100mg): Oral administration at a dose of 100 mg/day, taken before bedtime.
Study summary
This study is a multicenter, single-arm, non-randomized, open-label trial designed to evaluate the efficacy and safety of chidamide and azacitidine in combination with prednisone, cyclophosphamide, and thalidomide (CAPCT regimen) in patients with peripheral T-cell lymphoma (PTCL). A total of 58 patients with PTCL are planned to be enrolled after providing written informed consent and meeting all eligibility criteria. Enrolled patients will receive the CAPCT regimen, with each cycle consisting of 21 days, for a total of 6 cycles. Participants who do not experience disease progression or unacceptable toxicity after 6 cycles of combination therapy will continue to receive the CPCT regimen (chidamide combined with prednisone, cyclophosphamide, and thalidomide) for up to 6 months, followed by chidamide monotherapy as maintenance treatment. The primary efficacy endpoint is objective response rate (ORR).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 1\. Patients with histopathologically confirmed peripheral T-cell lymphoma (PTCL), with exclusion of NK/T-cell lymphoma.
* 2\. Patients who are treatment-naïve or have relapsed/refractory disease.
* 3\. Patients who are intolerant to standard chemotherapy regimens for various reasons, including those aged ≥75 years, or those aged \<75 years but deemed by the investigator to be unsuitable for or unable to tolerate chemotherapy.
* 4\. Patients aged ≥18 years, male or female.
* 5\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3.
* 6\. Absolute neutrophil count ≥1.5×10⁹/L, platelet count ≥50×10⁹/L, and hemoglobin ≥70 g/L.
* 7\. Estimated life expectancy ≥3 months.
* 8\. Voluntary signing of written informed consent.
Exclusion Criteria:
* 1\. Pregnant or lactating women, or fertile patients of childbearing potential who are unwilling to adopt contraceptive measures.
* 2\. Patients with chronic heart failure of New York Heart Association (NYHA) functional class III or IV; or those with a history of any of the following cardiac conditions within 6 months: acute coronary syndrome; acute heart failure (NYHA functional class III or IV); or significant ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, or sudden cardiac death after resuscitation).
* 3\. Hepatic dysfunction (total bilirubin \>1.5× the upper limit of normal \[ULN\]; alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\] \>2.0× ULN, or \>5× ULN in patients with hepatic involvement); or renal dysfunction (serum creatinine \>1.5× ULN).
* 4\. Confirmed central nervous system (CNS) involvement by lymphoma.
* 5\. Receipt of prior myelosuppressive symptomatic treatment within 7 days before enrollment.
* 6\. Active hemorrhage/bleeding.
* 7\. Patients with acquired immunodeficiency syndrome (AIDS), syphilis, or active hepatitis B (HBV DNA \>1×10⁵ copies/mL) or hepatitis C.
* 8\. Receipt of grade II or higher surgery within 3 weeks prior to treatment.
* 9\. Psychiatric disorders or inability to provide informed consent.
* 10\. Patients deemed by the investigator to be unsuitable for participation in this trial.
* 11\. Known allergy to any component of the investigational drug.
Primary outcome measure(s)
Objective Response Rate（ORR） — Up to 2 years The proportion of patients who achieve a CR 、CRu and PR
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital of Nanjing Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.